Differential FDG accumulation associated with GLUT-1 expression in a patient with lymphoma

Annals of Nuclear Medicine

Volumn 17, Issue 4, 2003, Pages 327-331

  Koga, Hirofumi ^a   Matsuo, Yoshio ^a   Sasaki, Masayuki ^a   Nakagawa, Makoto ^a   Kaneko, Koichiro ^a   Hayashi, Kazutaka ^a   Kuwabara, Yasuo ^a   Honda, Hiroshi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

FDG PET; GLUT 1; Malignant lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4;

ADULT; ARTICLE; AXILLARY LYMPH NODE; B CELL LYMPHOMA; BIOACCUMULATION; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CERVICAL LYMPH NODE; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DRUG UPTAKE; HUMAN; HUMAN TISSUE; IMAGE RECONSTRUCTION; IMMUNOHISTOCHEMISTRY; LYMPH NODE BIOPSY; LYMPHADENOPATHY; LYMPHOMA; LYMPHOMA CELL; MALE; MESENTERY LYMPH NODE; PARAAORTIC LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL TRANSPLANTATION;

EID: 0042514721     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02988530     Document Type: Article

References (34)

1. Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med 1987; 28: 288-292.
2. Okada J, Yoshikawa K, Imazeki K, Minoshima S, Uno K, Itami J, et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med 1991; 32: 686-691.
3. 18F]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994; 190: 111-116.
4. Buchmann I, Reinhardt M, Elsner K, Bunjes D, Altehoefer C, Finke J, et al. 2-(fluorine-18) fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. Cancer 2001; 91: 889-899.
5. Hoh CK, Glaspy J, Rosen P, Dahlbom M, Lee SJ, Kunkel L, et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997; 38: 343-348.
6. 18F]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997; 203: 795-800.
7. Stumpe KDM, Urbinelli M, Steinert HC, Glanzmann HC, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998; 25: 721-728.
8. 18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 1998; 9: 1117-1122.
9. 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 1999; 20: 13-20.
10. 18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 2001; 12: 825-830.
11. Sasaki M, Kuwabara Y, Koga H, Nakagawa M, Chen T, Kaneko K, et al. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. Ann Nucl Med 2002; 16: 337-345.
12. Shah N, Hoskin P, McMillan A, Gibson P, Lowe J, Wong WL. The impact of FDG positron emission tomography imaging on the management of lymphomas. Br J Radiol 2000; 73: 482-487.
13. 18F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med 2001; 42: 1139-1143.
14. Römer W, Hanauske AR, Ziegler S, Thödtmann R, Weber W, Fuchs C, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91: 4464-4471.
15. 18FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma - comparison with CT. Leukemia and Lymphoma 2000; 39: 5-6.
16. 18F] FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F] FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19: 414-419.
17. Okada J, Yoshikawa K, Itami M, Imaseki K, Uno K, Itami J, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992; 33: 325-329.
18. Rodriguez M, Rehn S, Ahlstrom H, Sundstrom C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 1995; 36: 1790-1796.
19. Lapela M, Leskinen S, Minn HR, Lindholm P, Klemi PJ, Söderström KO, et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 1995; 86: 3522-3527.
20. 18F-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 1999; 10: 1185-1189.
21. Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl RL. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 1999; 40: 556-565.
22. 18F] fluoro-2-deoxy-D-glucose (FDG) incorporation. Nucl Med Biol 2001; 28: 1-4.
23. Waki A, Kato H, Yano R, Sadato N, Yokoyama A, Ishii Y, et al. The importance of glucose transport activity as the rate-limiting step of 2-deoxyglucose uptake in tumor cells in vitro. Nucl Med Biol 1998; 25: 593-597.
24. Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995; 36: 1811-1817.
25. Warburg OH. The metabolism of tumors. London; Constable, 1930: 29-169.
26. Shinohara Y. Identification and characterization of hexokinase isoform predominantly expressed in malignant tumor cells. Yakugaku Zasshi 2000; 130: 657-666. [Japanese]
27. Katabi MM, Chan HL, Karp SE, Batist G. Hexokinase type II: a novel tumor-specific promoter for gene-targeted therapy differentially expressed and regulated in human cancer cells. Hum Gene Ther 1999; 10: 155-164.
28. Brown RS, Goodman TM, Zasadny KR, Greenson JK, Wahl RL. Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nucl Med Biol 2002; 29: 443-453.
29. 18F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med 2002; 43: 173-180.
30. Nelson CA, Wang JQ, Leav I, Crane PD. The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to 3H-2-deoxyglucose retention in murine tumor models. Nucl Med Biol 1996; 23: 533-541.
31. 18F-FDG in the staging of non-Hodgkin's lymphoma. J Nucl Med 2001; 42: 601-608.
32. Mochizuki T, Tsukamoto E, Kuge Y, Kanegae K, Zhao S, Hikosaka K, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med 2001; 42: 1551-1555.
33. Mueckler M. Facilitative glucose transporters. Eur J Biochem 1994; 219: 713-725.
34. Adams V, Kempf W, Hassam S, Briner J. Determination of hexokinase isozyme I and II by RT-PCR: increased hexokinase II isozyme in human renal cell carcinoma. J Biochem Mol Med 1995; 54: 53-58.